Abbott Cardiovascular Franchise Swells; Combo Waves Will Crest in 2009
Executive Summary
Abbott plans to submit a fixed-dose statin-fenofibrate combination with AstraZeneca's Crestor in 2009, the company reported during a June 18 sales and earnings call
You may also be interested in...
Merck’s Cordaptive “Not Approvable,” But Clark Not Giving Up On Combo
Although Merck's cholesterol combination Cordaptive failed to clear FDA on the first pass, the company is clear that FDA's decision does not signal the end of development for the cholesterol drug
Merck’s Cordaptive “Not Approvable,” But Clark Not Giving Up On Combo
Although Merck's cholesterol combination Cordaptive failed to clear FDA on the first pass, the company is clear that FDA's decision does not signal the end of development for the cholesterol drug
Humira sales growth
Sales of the TNF inhibitor grew 40 percent in the third quarter to $427 mil. in the U.S. compared to the year-ago period, Abbott reports. Humira (adalimumab), which recently underwent a successful launch for Crohn's disease, also gained share in the rheumatology, dermatology and gastroenterology markets (1"The Pink Sheet" July 23, 2007, p. 11). Worldwide Humira sales were $803 mil. in the quarter, up 48.5 percent from 2006, leading the company to predict 2007 sales of $3 bil. for Abbott's leading product. Overall, Abbott reports a 22.2 percent increase in global pharmaceutical sales and U.S. pharmaceutical sales rose 17.5 percent in the quarter...